Taken together, our data demonstrate that TPM cancer cells can be made competent to undergo intrinsic apoptosis when treated with MEKi and BCL-2 family inhibitors, and that BIM is likely a critical mediator of MEKi-induced apoptosis in cells. Here, BCL2L11 is linked to cancer.